In recent years, PD-1/PD-L1 immunotherapy combined with radiotherapy, chemotherapy, and molecular targeted therapy has benefited some people who are not suitable for PD-1/PD-L1 inhibitors (Keir et al., 2008; Li et al., 2016); and the effective targeted therapeutic inhibitors for CRC are still lacking. Here, CD274 is linked to colorectal carcinoma.